Curis reports Q4 EPS (12c), consensus (13c)

Reports Q4 revenue $2.9M, consensus $3.18M. "We are pleased to announce that we have completed enrollment of the 9 additional patients requested by FDA ahead of schedule. This is an important step towards resolving the partial clinical hold in the TakeAim Leukemia study. We also look forward to discussions with FDA on the determination of the Recommended Phase 2 Dose, as we work with our clinical investigators to develop potential pivotal study designs for emavusertib," said James Dentzer, President and Chief Executive Officer of Curis.